Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:CAR_T-cell_therapy
|
| gptkbp:biological_source |
donor-derived T cells
|
| gptkbp:business_model |
adhered to in trials
|
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:2016 Phase 1 Cellectis multiple phases planned pending publication to be analyzed defined for trials adaptive design used to be reported NCT02746952 |
| gptkbp:collaboration |
various academic institutions
|
| gptkbp:collaborations |
with other biotech firms
|
| gptkbp:collection |
systematic during trials
|
| gptkbp:developed_by |
Cellectis
|
| gptkbp:dosage_form |
determined in trials
|
| gptkbp:duration |
varies by patient
|
| gptkbp:eligibility |
defined by specific criteria
|
| gptkbp:feedback |
collected during trials
|
| gptkbp:funding |
secured from various sources
|
| gptkbp:future_prospects |
planned for additional indications
|
| https://www.w3.org/2000/01/rdf-schema#label |
UCART123
|
| gptkbp:investigates |
ongoing
|
| gptkbp:is_a_platform_for |
gene editing
|
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:is_monitored_by |
implemented during trials
|
| gptkbp:is_tested_for |
under investigation
|
| gptkbp:manufacturing_process |
GMP-compliant
|
| gptkbp:mechanism_of_action |
genetically modified T cells
targeting CD19 expressing cells |
| gptkbp:origin |
allogeneic T cells
|
| gptkbp:partnerships |
with pharmaceutical companies
|
| gptkbp:patient_population |
adult and pediatric patients
|
| gptkbp:potential_indications |
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma |
| gptkbp:provides_guidance_on |
relapsed or refractory cases
|
| gptkbp:publications |
related to its development
|
| gptkbp:recruitment |
ongoing
|
| gptkbp:regulatory_compliance |
investigational
not yet obtained |
| gptkbp:related_products |
submitted
|
| gptkbp:related_to |
Cellectis' UCART technology
|
| gptkbp:research |
conducted
|
| gptkbp:research_areas |
oncology
|
| gptkbp:research_focus |
CAR-T cell engineering
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
under investigation
|
| gptkbp:safety_measures |
ongoing during trials
|
| gptkbp:scientific_goals |
improve patient outcomes
|
| gptkbp:service_frequency |
single infusion
|
| gptkbp:side_effect |
monitored during trials
|
| gptkbp:supply_chain |
critical for trial success
managed by Cellectis |
| gptkbp:targets |
gptkb:CD19
|
| gptkbp:therapeutic_goal |
achieve remission
|
| gptkbp:treatment |
monitored closely
assessed in trials |
| gptkbp:used_for |
treatment of B-cell malignancies
|